Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Modulation of p300 to protect against doxorubicin-mediated cardiotoxicity

EF 2020-21

Résumé
Doxorubicin (Dox) is a widely prescribed and highly effective chemotherapy drug that is used to treat a wide variety of cancers. However, it is also known to have adverse effects on cardiac function, and can cause arrhythmia, cardiomyopathy, left ventricular dysfunction, and congestive heart failure. Dox acts through a variety of molecular mechanisms, including free radical production, induction of apoptosis, and extracellular matrix remodelling. The major mechanism by which Dox induces apoptosis involves increasing the activity of the tumour suppressor protein p53, which activates apoptotic pathways in the cell. Dox increases p53 activity through the production of reactive oxygen species, direct activation of p53, and decreased degradation of the lysine acetyltransferase p300, which activates p53. Epigenetic modifications such as acetylation are important in the heart because cardiac muscle cells do not have a high turnover rate. Consequently, preventing post-translational acetylation of p53 by p300 may be an important strategy to limit Dox cardiotoxicity. Curcumin, a natural product found in turmeric has been shown to inhibit p300 by promoting its degradation by proteasomes. In addition, curcumin has been shown to have its own anti-cancer properties. However, a drawback of curcumin is its low bioavailability and low half life, resulting in poor absorption through oral consumption. Recently, a new formulation of curcumin, named theracurmin, was developed that is 27x more bioavailable than curcumin alone. We believe that through its effects on p300, theracurmin will protect Dox-treated mice from Dox-mediated cardiotoxicity.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449750
Name
Lee Jong-Hwan J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Modulation of p300 to protect against doxorubicin-mediated cardiotoxicity
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiotoxicity; Cardiovascular; Doxorubicin
Abstract
Doxorubicin (Dox) is a widely prescribed and highly effective chemotherapy drug that is used to treat a wide variety of cancers. However, it is also known to have adverse effects on cardiac function, and can cause arrhythmia, cardiomyopathy, left ventricular dysfunction, and congestive heart failure. Dox acts through a variety of molecular mechanisms, including free radical production, induction of apoptosis, and extracellular matrix remodelling. The major mechanism by which Dox induces apoptosis involves increasing the activity of the tumour suppressor protein p53, which activates apoptotic pathways in the cell. Dox increases p53 activity through the production of reactive oxygen species, direct activation of p53, and decreased degradation of the lysine acetyltransferase p300, which activates p53. Epigenetic modifications such as acetylation are important in the heart because cardiac muscle cells do not have a high turnover rate. Consequently, preventing post-translational acetylation of p53 by p300 may be an important strategy to limit Dox cardiotoxicity. Curcumin, a natural product found in turmeric has been shown to inhibit p300 by promoting its degradation by proteasomes. In addition, curcumin has been shown to have its own anti-cancer properties. However, a drawback of curcumin is its low bioavailability and low half life, resulting in poor absorption through oral consumption. Recently, a new formulation of curcumin, named theracurmin, was developed that is 27x more bioavailable than curcumin alone. We believe that through its effects on p300, theracurmin will protect Dox-treated mice from Dox-mediated cardiotoxicity.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lee, Jong-Hwan J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~